Bogle Investment Management’s Adverum Biotechnologies ADVM Stock Holding History

Bogle Investment Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,905	Closed	-$154K	–	266
2018 Q2	$154K	Sell	2,905 -268	-8%	-$16.1K	0.01%	270
2018 Q1	$184K	Buy	+3,173	New	+$198K	0.01%	294
2017 Q1	–	Sell	-3,756	Closed	-$108K	–	295
2016 Q4	$108K	Sell	3,756 -6,082	-62%	-$199K	0.01%	321
2016 Q3	$404K	Sell	9,838 -4,814	-33%	-$183K	0.03%	313
2016 Q2	$463K	Buy	14,652 +2,316	+19%	+$105K	0.03%	325
2016 Q1	$637K	Buy	12,336 +8,411	+214%	+$470K	0.04%	310
2015 Q4	$373K	Sell	3,925 -26,200	-87%	-$2.3M	0.03%	328
2015 Q3	$2.48M	Buy	+30,125	New	+$3.85M	0.18%	156

Other funds holding ADVM

MSU

Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

CHP

Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Bogle Investment Management's ADVM Position: Q3 2018 in Review

Bogle Investment Management sold out of Adverum Biotechnologies (ADVM) in Q3 2018, closing a stake of 2,905 shares — an estimated $154K sold.

Bogle Investment Management first reported a position in ADVM in Q3 2015 and held it in 8 quarters. The position peaked at $2.48M in Q3 2015. 101 funds tracked by Wall St. Rank hold ADVM as of Q3 2018.

Bogle Investment Management reported no remaining Adverum Biotechnologies position as of Q3 2018 after selling out during the quarter.
Bogle Investment Management sold 2,905 Adverum Biotechnologies shares in Q3 2018, an estimated $154K.
Bogle Investment Management first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 8 quarters.
Bogle Investment Management's Adverum Biotechnologies position peaked at $2.48M in Q3 2015.
101 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2018.

Based on Bogle Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.